Inato, the leading technology platform enabling access to inclusive clinical trials, today announced the close of $20 million in Series A2 funding from existing and new investors. The fundraise includes return and lead investor…
Continue Reading
DarioHealth, a digital chronic condition management platform, announced Eitan Shay is joining the company in its newly created position of chief product officer. Shay was previously in leadership roles at Livongo, Teladoc Health and…
Continue Reading
Almost three-quarters of all clinical trials are run by the same 5% of academic sites, according to Inato CEO Kourosh Davarpanah.
“This lack of patient access causes trial delays and costs to skyrocket, ultimately constraining…
Marie E. Lamont, Global RWE Data Strategy, Access & Enablement at IQVIA and General ManagerThe American Cancer Society’s Cancer Statistics 2023 report highlighted a few major accomplishments within oncology, such as decreased cancer mortality…
Continue Reading
What You Should Know:– Protai, a proteomics and AI-powered drug discovery startup revolutionizing the way new drugs are discovered, today announced a $12 million extension of its seed round, bringing the total amount to…
Continue Reading
Seagen, the biotech company Pfizer is buying for $43 billion, is considered a pioneer in the class of cancer drugs called antibody drug conjugates. But the first ADC to reach the market wasn’t a…
Continue Reading
Novo Nordisk is slashing prices of several insulin products by up to 75% amid growing political scrutiny on the prices of these older but still expensive diabetes medicines. The announcement Tuesday comes two weeks…
Continue Reading
In todays fast-paced world, it is easy to miss out on important information, especially if you are trying to keep up with a lot of different sources. That is where the daily digest comes in – it is a tool that compiles all the posts created on the previous day, providing you with a convenient […]
Continue Reading
What You Should Know:– Sanofi has agreed to acquire Provention Bio, Inc., a U.S.-based, publicly traded biopharmaceutical company focused on intercepting and preventing immune-mediated diseases including type 1 diabetes (T1D), for $25.00 per share in cash, representing an equity…
Continue Reading
Epstein-Barr is among the most common viruses, but no vaccines are available to prevent its infection. Merck is joining the pursuit for a vaccine by striking a deal with Opko Health, paying $50 million…
Continue Reading
